AU2021225617A1 - Functional human corneal endothelial cells and application thereof - Google Patents

Functional human corneal endothelial cells and application thereof Download PDF

Info

Publication number
AU2021225617A1
AU2021225617A1 AU2021225617A AU2021225617A AU2021225617A1 AU 2021225617 A1 AU2021225617 A1 AU 2021225617A1 AU 2021225617 A AU2021225617 A AU 2021225617A AU 2021225617 A AU2021225617 A AU 2021225617A AU 2021225617 A1 AU2021225617 A1 AU 2021225617A1
Authority
AU
Australia
Prior art keywords
cell
cells
corneal endothelial
functional
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021225617A
Other languages
English (en)
Inventor
Junji Hamuro
Shigeru Kinoshita
Chie Sotozono
Munetoyo Toda
Morio Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto Prefectural PUC
Original Assignee
Kyoto Prefectural PUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto Prefectural PUC filed Critical Kyoto Prefectural PUC
Publication of AU2021225617A1 publication Critical patent/AU2021225617A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
AU2021225617A 2020-02-27 2021-02-26 Functional human corneal endothelial cells and application thereof Pending AU2021225617A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-032139 2020-02-27
JP2020032139 2020-02-27
PCT/JP2021/007490 WO2021172554A1 (ja) 2020-02-27 2021-02-26 ヒト機能性角膜内皮細胞およびその応用

Publications (1)

Publication Number Publication Date
AU2021225617A1 true AU2021225617A1 (en) 2022-10-13

Family

ID=77491963

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021225617A Pending AU2021225617A1 (en) 2020-02-27 2021-02-26 Functional human corneal endothelial cells and application thereof

Country Status (9)

Country Link
US (1) US20230257700A1 (https=)
EP (1) EP4116411A4 (https=)
JP (2) JP7807073B2 (https=)
KR (1) KR20220146552A (https=)
CN (1) CN115427551A (https=)
AU (1) AU2021225617A1 (https=)
BR (1) BR112022017180A2 (https=)
CA (1) CA3173725A1 (https=)
WO (1) WO2021172554A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021366805B2 (en) 2020-10-22 2025-04-24 Kyoto Prefectural Public University Corporation A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells
WO2024210619A1 (ko) * 2023-04-06 2024-10-10 재단법인 아산사회복지재단 줄기세포의 각막 내피 세포로의 직접 분화 유도용 조성물 및 이를 이용한 직접 분화 유도 방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
JP3421217B2 (ja) 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
AU9646198A (en) 1997-10-22 1999-05-10 Nippon Shinyaku Co. Ltd. Isoquinoline derivative and drug
WO1999061403A1 (en) 1998-05-25 1999-12-02 Santen Pharmaceutical Co., Ltd. Novel vinylbenzene derivatives
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1541559A4 (en) 2002-07-22 2007-08-22 Asahi Kasei Pharma Corp 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE
CA2400996A1 (en) 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
WO2005003101A2 (en) 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
WO2005039564A1 (en) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
WO2005034866A2 (en) 2003-10-06 2005-04-21 Glaxo Group Limited Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
JP2007507547A (ja) 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，７−二置換アザベンゾイミダゾールの調製
ES2387780T3 (es) 2003-10-06 2012-10-01 Glaxosmithkline Llc Preparación de azabencimidazoles 1,6-disustituidos como inhibidores de quinasas
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
JP2007015928A (ja) 2003-10-15 2007-01-25 Ube Ind Ltd 新規オレフィン誘導体
CA2556589A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
AR049333A1 (es) 2004-04-02 2006-07-19 Vertex Pharma Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
WO2006057270A1 (ja) 2004-11-26 2006-06-01 Asahi Kasei Pharma Corporation 含窒素３環化合物
CA2621181C (en) 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
JP5761827B2 (ja) * 2011-07-15 2015-08-12 国立大学法人大阪大学 角膜内皮細胞の調製方法
EP2765188B1 (en) 2011-10-06 2017-12-06 Keio University Method for producing corneal endothelial cell
EP3029140A4 (en) * 2013-07-30 2017-06-28 Kyoto Prefectural Public University Corporation Corneal endothelial cell marker
WO2016129654A1 (ja) * 2015-02-12 2016-08-18 国立大学法人 東京大学 角膜内皮前駆細胞の調製方法
EP3416658B1 (en) * 2016-02-15 2023-03-22 Kyoto Prefectural Public University Corporation Human functional corneal endothelial cell and application thereof
JP2020032139A (ja) 2018-08-31 2020-03-05 株式会社三洋物産 遊技機

Also Published As

Publication number Publication date
BR112022017180A2 (pt) 2022-10-18
EP4116411A1 (en) 2023-01-11
CN115427551A (zh) 2022-12-02
JPWO2021172554A1 (https=) 2021-09-02
WO2021172554A1 (ja) 2021-09-02
KR20220146552A (ko) 2022-11-01
CA3173725A1 (en) 2021-09-02
EP4116411A4 (en) 2024-04-17
US20230257700A1 (en) 2023-08-17
JP2026027335A (ja) 2026-02-18
JP7807073B2 (ja) 2026-01-27

Similar Documents

Publication Publication Date Title
Hollywood et al. Use of human induced pluripotent stem cells and kidney organoids to develop a cysteamine/mTOR inhibition combination therapy for cystinosis
JP7453669B2 (ja) ヒト機能性角膜内皮細胞およびその応用
Bednash et al. Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity
Zhang et al. Human macular Müller cells rely more on serine biosynthesis to combat oxidative stress than those from the periphery
Cheong et al. Identification of cell surface markers glypican-4 and CD200 that differentiate human corneal endothelium from stromal fibroblasts
Anderson et al. Sterols lower energetic barriers of membrane bending and fission necessary for efficient clathrin-mediated endocytosis
Tu et al. USP15 enhances the proliferation, migration, and collagen deposition of hypertrophic scar–derived fibroblasts by deubiquitinating TGF-βR1 In Vitro
Tian et al. ACLY ubiquitination by CUL3-KLHL25 induces the reprogramming of fatty acid metabolism to facilitate iTreg differentiation
JP2026027335A (ja) ヒト機能性角膜内皮細胞およびその応用
An et al. Vesicular formation regulated by ERK/MAPK pathway mediates human erythroblast enucleation
Kosmas et al. TSC2 interacts with HDLBP/vigilin and regulates stress granule formation
Cheng et al. Expression and phosphorylation of the AS160_v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myeloma
Melo et al. HtrA1 mediated intracellular effects on tubulin using a polarized RPE disease model
Tajhya et al. Functional KCa1. 1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblasts
Machado et al. L-plastin Ser5 phosphorylation is modulated by the PI3K/SGK pathway and promotes breast cancer cell invasiveness
Ji et al. High glucose-induced p66Shc mitochondrial translocation regulates autophagy initiation and autophagosome formation in syncytiotrophoblast and extravillous trophoblast
Zhai et al. PI3K/AKT/Afadin signaling pathway contributes to pathological vascularization in glioblastomas
Tu et al. Sestrin-mediated inhibition of stress-induced intervertebral disc degradation through the enhancement of autophagy
Wei et al. Plasma exosomes from patients with active thyroid-associated orbitopathy induce inflammation and fibrosis in orbital fibroblasts
Renaud et al. Multiomic analysis of papillary thyroid cancers identifies BAIAP2L1-BRAF fusion and requirement of TRIM25, PDE5A and PKCδ for tumorigenesis
Liu et al. Proliferation of renal macrophage via MR/CSF1 pathway induced with aldosterone and inhibited by esaxerenone
Forbes et al. The protein-tyrosine phosphatase, SRC homology-2 domain containing protein tyrosine phosphatase-2, is a crucial mediator of exogenous insulin-like growth factor signaling to human trophoblast
HK40078942A (en) Functional human corneal endothelial cells and application thereof
Sun et al. CRB2 depletion induces YAP signaling and disrupts mechanosensing in podocytes
Zou et al. Single-cell atlas profiling revealed cellular characteristics and dynamic changes after PD-1 blockade therapy of brain metastases from laryngeal squamous cell carcinoma